Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KIT 13

Next Previous
Drug Profile

KIT 13

Alternative Names: KIT-13

Latest Information Update: 21 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NeuroCores
  • Class Plasmalogens; Small molecules
  • Mechanism of Action Brain derived neurotrophic factor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Rett syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Rett syndrome

Most Recent Events

  • 21 May 2025 Preclinical trials in Rett syndrome in USA (unspecified route), before May 2025 (NeuroCores pipeline, May 2025)
  • 21 May 2025 NeuroCores plans a clinical trial in Rett syndrome in fourth quarter of 2025 (NeuroCores pipeline, May 2025)
  • 31 Mar 2023 KIT 13 receives Rare Pediatric Disease Designation (RPDD) for Rett syndrome in USA, in March 2023 (NeuroCores website, May 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top